KV Pharmaceutical Files for Chapter 11 - Wall Street Journal
08/06/12
![]()
KV Pharmaceutical Files for Chapter 11
Wall Street Journal
K-V Pharmaceutical Co. filed for Chapter 11 bankruptcy, a move it said was propelled by the U.S. Food and Drug Administration's failure to enforce orphan drug exclusivity granted to K-V's key premature-birth drug, Makena. Chief Executive Greg Divis ...
KV Pharma seeks Chapter 11 bankruptcy protectionSan Francisco Chronicle
[more]
Wall Street Journal
K-V Pharmaceutical Co. filed for Chapter 11 bankruptcy, a move it said was propelled by the U.S. Food and Drug Administration's failure to enforce orphan drug exclusivity granted to K-V's key premature-birth drug, Makena. Chief Executive Greg Divis ...
KV Pharma seeks Chapter 11 bankruptcy protectionSan Francisco Chronicle
- Feeds Categories: